Search
Trilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigationalG1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for … [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.
Categories: Detoxifying Agents for Antineoplastic TreatmentAbrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … JAK inhibitors recently attracted more attention as potential treatments for inflammatory disorders, as JAK inhibition is associated with rapid and sustained anti-inflammatory efects.
Categories: Agents for Dermatitis, Excluding CorticosteroidsGentamicin
go.drugbank.com/drugs/DB00798ApprovedInvestigationalVet approved[A234364] This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects. … [A234339,A234354] Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by
Categories: Antibiotics for Topical Use, Antibacterials for Systemic UseLusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta. … TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well
Piracetam
go.drugbank.com/drugs/DB09210ApprovedWithdrawnEvidence to support its use for many conditions is unclear. … It is not approved for any medical or dietary use by the FDA.
Categories: Psychostimulants, Agents Used for ADHD and NootropicsCanagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalIt was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type … Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897].
Acamprosate
go.drugbank.com/drugs/DB00659ApprovedInvestigational[A229073] Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. … Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity,
Maribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigationalMaribavir was approved by the FDA in November 2021, under the name Livtencity (Takeda), for the treatment of resistant CMV infections in post-transplant patients.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UsePoliovirus type 2 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10796ApprovedInvestigationalPoliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis
Mixtures: Hexaxim Suspension for Injection, BOOSTRIX POLIO SUSPENSION FOR INJECTIONPentobarbital
go.drugbank.com/drugs/DB00312ApprovedVet approvedIt is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration.